Patents by Inventor Arathi Krishnakumar

Arathi Krishnakumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSGL-1 Antagonists and Uses Thereof
    Publication number: 20240228653
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Application
    Filed: December 18, 2023
    Publication date: July 11, 2024
    Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • PSGL-1 Antagonists and Uses Thereof
    Publication number: 20220298258
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Application
    Filed: March 15, 2022
    Publication date: September 22, 2022
    Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
    Patent number: 11306150
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • PSGL-1 Antagonists and Uses Thereof
    Publication number: 20190330364
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Application
    Filed: January 10, 2018
    Publication date: October 31, 2019
    Applicants: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal